Trial Profile
AN INVESTIGATION INTENDED TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF GENOTROPIN IN CHILDREN WITH SGA DWARFISM WITHOUT EPIPHYSEAL CLOSURE. (RETROSPECTIVE STUDY)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2020
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Growth disorders; Short stature
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 10 Mar 2017.
- 03 Mar 2017 Planned End Date changed from 1 Feb 2017 to 10 Mar 2017.